Navigation Links
Feinstein Institute researcher publishes new perspective on sepsis

MANHASSET, NY In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis, which kills millions worldwide every year, including more than 200,000 Americans.

Sepsis occurs when molecules released into the bloodstream to fight an injury or infection trigger inflammation throughout the body. Inflammation is necessary for maintaining good health without inflammation, wounds and infections would never be controlled or heal. However, persistent and constant inflammation often results in organ dysfunction or damage, leading to death 28 to 50 percent of people who suffer from sepsis die from the condition. In addition to the toll in human lives, sepsis costs healthcare systems billions of dollars each year much of the costs attributed to expenses incurred during weeks or months-long stays in intensive care units.

The review, co-written by Dr. Tracey and Clifford S. Deutschman, professor of Anesthesiology and Critical Care at the University of Pennsylvania, notes that unlike other major epidemic illnesses, treatment for sepsis is nonspecific and limited primarily to support of organ function and administration of intravenous fluids, antibiotics and oxygen. There are no approved drugs that specifically target sepsis. They argue that to develop therapeutic options that treat sepsis, a new approach might be needed.

Sepsis, Drs. Tracey and Deutschman wrote, "is not a stereotypical, steadily progressive immunological process that follows infection or injury; that innate and adaptive immune responses do not inevitably damage host cells; and that the long-held notion that sepsis is a distinct immunological disorder is incorrect. Rather, understanding sepsis requires reframing the research focus to identify immunometabolic and neurophysiological mechanisms of cellular and organ dysfunction."

The review explains that severe sepsis and persistent critical illness (PCI), which result in organ dysfunction that lasts for weeks or months, are not immunopathologies as previously thought. Immunopathology is a branch of medicine that deals with immune responses associated with disease. It includes the study of the pathology of an organism, organ system, or disease with respect to the immune system, immunity, and immune responses. Much of the efforts to treat sepsis have been focused in this area. Although much has been learned about sepsis and PCI as a result, this approach has not led to any currently approved targeted treatment.

Recent discoveries indicate that severe sepsis and PCI are not caused by immune system dysfunction alone, but also by a failure of homeostasis a failure in the body to maintain stability of its internal environment in response to changes in external conditions. Now that researchers know this, it will be crucially important to study aspects of homeostasis, including the deregulation of metabolism, neural reflexes, energy utilization and cell stress. Greater understanding in these areas has potential for resulting in improved and effective treatment for severe sepsis and PCI.


Contact: Emily Ng
North Shore-Long Island Jewish (LIJ) Health System

Related medicine news :

1. Feinstein Institute Researcher Joins International Partnership in Neuroscience Research
2. Feinstein Institute researchers show a genetic overlap in schizophrenia and cognitive ability
3. Feinstein Researcher Receives 2013 Best of Manhasset Award
4. Feinstein Institute Encourages Science Education for NY Area Middle and High School Students
5. Feinstein Institute Researcher Organizes LI Alzheimer’s Consortium
6. Feinstein Institute to Receive $330,000 Grant to Support Research of Childhood Cancer
7. North Shore-LIJ Health System's Feinstein Institute to Receive $250,000 Grant from Lymphoma Research Foundation Grant to support research of Chronic Lymphocytic Leukemia
8. Summer Benefit Concert Raised More Than $1.5 Million for Feinstein Institute
9. Long Island Bike Challenge Rides to Raise Money for North Shore-LIJ's Feinstein Institute of Medical Research
10. Feinstein Institute, Hofstra North Shore-LIJ School of Medicine at 36th Annual Conference on Shock
11. North Shore-LIJ's Feinstein Institute Hosts Academic Commencement and Convocation
Post Your Comments:
(Date:12/1/2015)... Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... coalition of obesity groups has filed a discrimination claim against the U.S. Department of ... coverage in their Affordable Care Act (ACA) plans are breaking the clause in the ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 2015 , ... Growth in medical payments per workers’ compensation claim in Louisiana ... and nonhospital care, according to a recent study by the Workers Compensation Research Institute ... found medical payments per claim with more than seven days of lost time continued ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that ... the pre-planned interim futility analysis of the intent-to-treat (ITT) ... issues were identified by the DMC. Both the DMC ... results are expected in the second half of 2016, ...
(Date:12/1/2015)... -- As enforcement of the Food and Drug ... approaches, InfiniTrak announced today new partnerships ... looming FDA regulations. --> ... with State Pharmacy Associations, an independent pharmacist association, ... exclusively provide the InfiniTrak track-and-trace software solution to ...
(Date:12/1/2015)... ) ... "Medium Molecular Weight Polyisobutylene Market for Gum ... - Global Industry Analysis, Size, Share, Growth, ... report to their offering. --> ... the "Medium Molecular Weight Polyisobutylene Market ...
Breaking Medicine Technology: